{"url":"https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/","title":"Erasca eyes RevMed's throne in RAS inhibitors","domain":"statnews.com","imageUrl":"https://images.pexels.com/photos/9574407/pexels-photo-9574407.jpeg?auto=compress&cs=tinysrgb&h=650&w=940","pexelsSearchTerm":"biotech","category":"Business","language":"en","slug":"61f9b12e","id":"61f9b12e-8e15-487d-9dee-842e519bd6d6","description":"Erasca Profile: STAT News profiles Erasca as a potential rival to Revolution Medicines in pan-RAS inhibitors for pancreatic cancer.[[1]](https://www.statne","summary":"## TL;DR\n- **Erasca Profile:** STAT News profiles Erasca as a potential rival to Revolution Medicines in pan-RAS inhibitors for pancreatic cancer.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[2]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock)\n- **Market Values:** Erasca's value nears $7 billion while Revolution Medicines exceeds $30 billion amid recent trial success.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[3]](https://companiesmarketcap.com/erasca/marketcap)\n- **Data Awaited:** Erasca expects early-stage ERAS-0015 results in May to test if it outperforms RevMed's drug.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[4]](https://www.tradingview.com/news/tradingview:b173e03f70568:0-erasca-narrows-timing-for-phase-1-eras-0015-monotherapy-data-to-mid-may-2026)\n\n## The story at a glance\nSTAT News columnist Adam Feuerstein examines whether Erasca, led by co-founder and CEO Jonathan Lim, can challenge Revolution Medicines (RevMed) with its pan-RAS inhibitor ERAS-0015 for pancreatic cancer. The piece highlights investor interest in Erasca as the \"poor man's\" RevMed following RevMed's recent phase 3 data showing 13.2 months median overall survival versus 6.7 months for chemotherapy.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[5]](https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit) This is reported now as Erasca's stock hits four-year highs ahead of its own phase 1 data readout, narrowed to mid-May.[[6]](https://finance.yahoo.com/markets/stocks/articles/erasca-eras-hits-4-high-011601777.html)[[4]](https://www.tradingview.com/news/tradingview:b173e03f70568:0-erasca-narrows-timing-for-phase-1-eras-0015-monotherapy-data-to-mid-may-2026)\n\n## Key points\n- Erasca focuses on ERAS-0015, a pan-RAS inhibitor in phase 1 (AURORAS-1 trial) for RAS-mutant solid tumors, including potential pancreatic cancer application.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)\n- Company described as \"poor man's Revolution Medicines\" due to similar approach but smaller $7 billion market value versus RevMed's over $30 billion.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[3]](https://companiesmarketcap.com/erasca/marketcap)\n- RevMed's recent phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer showed 13.2 months median overall survival (HR 0.40 vs chemotherapy).[[5]](https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit)[[7]](https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13)\n- Erasca plans initial phase 1 monotherapy data for ERAS-0015 in mid-May 2026, recently narrowed from first half of year.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[4]](https://www.tradingview.com/news/tradingview:b173e03f70568:0-erasca-narrows-timing-for-phase-1-eras-0015-monotherapy-data-to-mid-may-2026)\n- Jonathan Lim praises RevMed as pioneer after their data release last week.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)\n\n## Details and context\nErasca develops therapies for RAS/MAPK pathway-driven cancers, with ERAS-0015 as a pan-RAS molecular glue intended to block RAS signaling more potently than competitors, based on preclinical claims of 5-10x potency edge over RevMed's RMC-6236.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/) Early dose escalation in AURORAS-1 showed partial responses at low doses (8 mg daily) across RAS-mutant tumors, with favorable safety and pharmacokinetics, but full phase 1 data is pending.[[8]](https://www.erasca.com/news/erasca-announces-promising-early-clinical-data-for-eras-0015-and-2026-2027-milestones)\n\nRevMed's daraxonrasib sets a high bar: in RAS G12-mutated metastatic pancreatic ductal adenocarcinoma (90%+ of cases RAS-mutated), it nearly doubled survival versus chemotherapy in second-line setting, with full details at ASCO in late May.[[5]](https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit)[[9]](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-pivotal-phase-3-rasolute-302)\n\nThe article notes investor motivation to bet on Erasca as next big RAS player, amid stock surge to $21.85 four-year high (YTD +483%).[[6]](https://finance.yahoo.com/markets/stocks/articles/erasca-eras-hits-4-high-011601777.html)\n\n## Key quotes\n“RevMed has been a real pioneer in this space,” Erasca co-founder and CEO Jonathan Lim told me when we spoke on Tuesday. “What a day it was last week seeing their data with 13.2 months of median overall survival. It’s great for patients with pancreatic cancer.”[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)\n\n## Why it matters\nRAS mutations drive over 90% of pancreatic cancers, an area with few advances and dismal prognosis, so new inhibitors like ERAS-0015 could expand options if superior to daraxonrasib.[[7]](https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13) Investors face high stakes with Erasca's $7 billion valuation hinging on phase 1 data potentially validating or deflating \"next RevMed\" hype, affecting biotech funding in oncology.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/) Watch Erasca's mid-May readout and any RevMed ASCO updates, though early data may not predict pivotal trial outcomes.[[4]](https://www.tradingview.com/news/tradingview:b173e03f70568:0-erasca-narrows-timing-for-phase-1-eras-0015-monotherapy-data-to-mid-may-2026)[[9]](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-pivotal-phase-3-rasolute-302)\n\n## What changed\nRevMed's phase 3 trial established 13.2 months median overall survival benchmark in previously treated metastatic pancreatic cancer. Erasca now pursues ERAS-0015 phase 1 data in May as potential \"better\" alternative. This follows RevMed topline release on April 13, 2026.[[5]](https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit)\n\n## FAQ\nQ: What is ERAS-0015?\nA: ERAS-0015 is Erasca's pan-RAS molecular glue degrader in phase 1 AURORAS-1 trial for RAS-mutant solid tumors. Early dose escalation data showed partial responses at low doses with good safety and pharmacokinetics. Initial monotherapy results are due mid-May 2026.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)[[8]](https://www.erasca.com/news/erasca-announces-promising-early-clinical-data-for-eras-0015-and-2026-2027-milestones)\n\nQ: How does Erasca compare to Revolution Medicines?\nA: Erasca is called the \"poor man's\" RevMed due to similar pan-RAS approach but $7 billion valuation versus RevMed's $30 billion+. Investors seek Erasca as next big thing post-RevMed's pancreatic data success.[[1]](https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/)\n\nQ: What were RevMed's pancreatic cancer results?\nA: In phase 3 RASolute 302, daraxonrasib showed 13.2 months median overall survival versus 6.7 months for chemotherapy (HR 0.40, p<0.0001) in previously treated metastatic pancreatic ductal adenocarcinoma. Full data at ASCO May 2026.[[5]](https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit)\n\nQ: When is Erasca releasing ERAS-0015 data?\nA: Initial phase 1 monotherapy data from AURORAS-1 and partner trial JYP0015M101 expected no later than mid-May 2026, tightened from H1 2026 guidance.[[4]](https://www.tradingview.com/news/tradingview:b173e03f70568:0-erasca-narrows-timing-for-phase-1-eras-0015-monotherapy-data-to-mid-may-2026)","hashtags":["#biotech","#oncology","#cancerdrugs","#pancreaticcancer","#rasinhibitors","#stockmarket"],"sources":[{"url":"https://www.statnews.com/2026/04/23/erasca-oncology-cancer-drug-stock/","title":"Original article"},{"url":"https://companiesmarketcap.com/erasca/marketcap","title":""},{"url":"https://www.tradingview.com/news/tradingview:b173e03f70568:0-erasca-narrows-timing-for-phase-1-eras-0015-monotherapy-data-to-mid-may-2026","title":""},{"url":"https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit","title":""},{"url":"https://finance.yahoo.com/markets/stocks/articles/erasca-eras-hits-4-high-011601777.html","title":""},{"url":"https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13","title":""},{"url":"https://www.erasca.com/news/erasca-announces-promising-early-clinical-data-for-eras-0015-and-2026-2027-milestones","title":""},{"url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-pivotal-phase-3-rasolute-302","title":""}],"viewCount":4,"publishedAt":"2026-04-23T12:40:23.673Z","createdAt":"2026-04-23T12:40:23.673Z","articlePublishedAt":"2026-04-23T10:30:00.000Z"}